Vitamin B complex and homocysteine in chronic renal failure;Vitaminas B y homocisteína en la insuficiencia renal crónica

Nutricion Hospitalaria

Volumn 22, Issue 6, 2007, Pages 661-671

  Sánchez González, Cristina ^a   Planells, E ^a   Aranda, P ^a   Perez De La Cruz A ^b   Asensio, C ^b   Mataix, J ^a   Llopis, J ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Chronic renal failure; Cianocobalamine; Folates; Homocysteine; Predialysis; Pyridoxine; Riboflavin; Thiamine; Vitamins

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN B COMPLEX; WATER;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; HUMAN; HYPERHOMOCYSTEINEMIA; MORTALITY; NUTRITIONAL STATUS; PROTEIN METABOLISM; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR;

HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; VITAMIN B DEFICIENCY;

EID: 37149005432     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Chazot C, Kopple JD. Vitamin Metabolism and Requirements in Renal Disease and Renal Failure. En: Kopple JD, Massry SG, eds. Nutritional Management of Renal Disease. Philadelphia. Lippincott Williams and Wilkins. 2004: 315-356.
2. Frank T, Czeche K, Bitsch R, Stein G. Assessment of thiamin status in chronic renal failure patients, transplant recipients and hemodialysis patients receiving a multivitamin supplementation. Int J Vitam Nutr Res 2000; 70(4):159-66.
3. Porrini M, Simionetti P, Ciappellano S y cols. Thiamin, riboflavin and pyridoxine status in chronic renal insufficiency. Int J Vitam Nutr Res 1989; 59:304-308.
4. Lonergan ET, Semar M, Sterzel RB y cols. Erythrocyte transketolase activity in dialized patients. A reversible metabolic lesion of uremia. N Engl J Med 1971; 284:1399-1403.
5. Kopple JD, Dirige OV, Jacob M y cols. Transketolase activity in red blood cels in chronic uremia. Trans Am Soc Artif Intern Organs 1972; 18:250-256.
6. Gilmour ER, Hartley GH, Goodship THJ. Trace Elements and Vitamins in Renal Disease. En: Mitch WE, Klahr S, eds. Handbook of Nutrition and the Kidney. Philadelphia. Lippincott-Raven. 1998: 107-122.
7. Pietrzak I, Baczyk K, Mlynarczyk M, Kaczmarek M. Content of thiammin in plasma and erythrocytes in patients with end stage renal disease. Przegl Lel 1996; 53:423-426.
8. 6 in nephritic syndrome. Miner Electrolyte Metab 1992; 18:293-294.
9. Ihara M, Ito T, YAnagihara C y cols. Wernicke's encephalopathy associated with hemodialysis: report of two cases and review of the literature. Clin Neurol Neurosurg 1999; 101:118-121.
10. Sandoval E, Borja H, Gatica A. Wernicke's encephalopathy as a complication of chronic hemodialysis: report of one case. Rev Med Chil 1997; 125:582-585.
11. Frank T, Bitsch R, Maiwald J, Stein G. Alteration of thiamine pharmacokinetics by end- stage renal disease (ESRD). Int J Clin Pharmacol Ther 1999; 37(9):449-55.
12. Marumo F, Kamata K, Okubo M. Deranged concentrations of water-soluble vitamins in the blood of undialyzed and dialyzed patients with chronic renal failure. Int J Artif Organs 1986; 9(1):17-24.
13. Gentile MG, Manna GM, D'Amico G y cols. Vitamin nutrition in patients with chronic renal failure and dietary manipulation. Contrib Nephrol 1988; 65:43-50.
14. Stein G, Sperschneider H, Kopple S. Vitamin levels in chronic renal failure and need for supplementation. Blood Purif 1985; 3:52-62.
15. Kopple JD, Swendseid ME, Holliday MA y cols. Recommendations for nutritional evaluation of patients on chronic dialysis. Kidney Int Suppl 1975; 249-252.
16. 6 supplementation can improve peripheral polyneuropathy in patients with chronic renal failure on high-flux haemodialysis and human recombinant erythropoietin. Nephrol Dial Transplant 2000; 15:1410-1413.
17. 6 deficiency in uremia. Am J Clin Nutr 1975; 28:950-957.
18. 6 deficiency in uremia and its implications for the depression of immune responses. Kidney Int 1974; 5:233-239.
19. 6 deeficiency on food intake, growth, and renal function in chronically azotemic rats. JPEN J Parenter Enteral Nutr 1987; 11:398-402.
20. 6 deficiency in adults with chronic glomerulonephritis with and without the nephritic syndrome. Int J Vitam Nutr Res 1984; 54:313-319.
21. 6 deficiency caused by noncompetitive inhibition of pyridoxal kinase. J Lab Clin Med 1989; 113:15-22.
22. Kopple JD, Mercurio K, Blumenkrantz MJ y cols. Daily requirement for pyridoxine supplements in chronic renal failure. Kidney Int 1981; 19:694-704.
23. 6-deficient uremic man. J Lab Clin Med 1977; 90:632-637.
24. Mydlik M, Derzsiova K. Vitamin levels in the serum and erythrocytes during erythropoietin therapy in hemodialyzed patients. Bratisl Lek Listy 1999; 100:426-431.
25. Hörl WH. Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrol Dial Transplant 1999; 14:50-60.
26. 6 and its requirement in chronic renal failure. Kidney Int Suppl. 1997; 62:S56-59.
27. Chauveau P, Chadefaux B, Coude M y cols. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 1996; 22:106-109.
28. Arnadottir M, Brattstorm L, Simonsen O y cols. The effect of the high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993; 40:236-240.
29. Said HM, Varizi ND, Kariger RK y cols. Intestinal absorption of 5-methyltetrahydrofolate in experimental uremia. Acta Vitaminol Enzimol 1984; 6:339-346.
30. Jenette JC, Goldman ID. Inhibition of the membrane transport of folates by anions retained in uremia. J Lab Clin Med 1975; 86:834-843.
31. Livan E, Tamura T, Johnston K y cols. Plasma folate conjugase activities and folate concentrations in patients receiving hemodialysis. J Nutr Biochem 1994; 5:504-508.
32. Paine CJ, Hargrove MD, Eichner ER. Folic acid binding protein and folate balance in uremia. Arch Intern Med. 1976; 136(7):756-60.
33. Hampers CL, Streiff R, Nathan DG y cols. Megaloblastic hematopoiesis in uremia and in patients on long-term hemodialysis. N Engl J Med 1967; 276:551-554.
34. Siddiqui J, Freeburger R, Freeman RM. Folic acid, hypersegmented polymorphonuclear leukocytes and the uremic syndrome. Am J Clin Nutr 1970; 23:11-16.
35. 12 and folic acid in children with chronic renal failure. Pol Merkuriusz Lek 2000; 8:268-269.
36. Pronai W, Riegler-Keil M, Silberbauer K, Stockenhuber F. Folic acid supplementation improves erythropoietin response. Nephron 1995; 71:395-400.
37. Ono K, Hisasue Y. Is folate supplementation necessary in hemodialysis patients on erithropoietin therapy. Clin Nephrol 1992; 38:290-292.
38. Perna AF, Santo NG. Homocysteine. En: Kopple JD, Massry SG, eds. Nutritional Management of Renal Disease. Philadelphia. Lippincott Williams and Wilkins. 2004: 118-124.
39. Carluccio F, Siems W, Stefanelli G, Sommerburg O, Grune T, Riedel E, Hampl H. Homocysteine in chronic renal failure in relation to renal anemia and to oxidative stress parameters 4-hydroxynonenal and malondialdehyde. Clinical Nephrology 2002; 58:26-30.
40. Zhang C, Cai Y, Adachi MT, Oshiro S, Aso T, Kaufman RJ, Kitajima S. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. Biol Chem 2001; 276:35867-35874.
41. Lentz SR. Mechanism of thrombosis in hyperhomocysteinemia. Curr Opin Hematol 1998; 5:343-349.
42. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: results from the Third National Health and Nutrition Examination Survey. Am Heart J 2000; 139:446-53.
43. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27:517-527.
44. Wouters MG, Moorrees MT, Van der Mooren MJ y cols. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995; 25: 801-805.
45. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2.693-98.
46. Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middled-aged and elderly subjects. J Intern Med 1994; 236:633-641.
47. Robinson K, Mayer EL, Miller DP y cols. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92:2825-30.
48. De Bree A, Verschuren WMM, Kromhout D, Kluijtmans AJ, Blom H. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002; 54:599-618.
49. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52(1):10-20.
50. Skoupy S, Födinger M, Veitl M, Perschl A, Puttinger H, Röhrer C, Schindler K, Vychytil A, Hörl W, Sunder-Plassmann G. Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients. J Am Soc Nephrol 2002; 13:1331-1337.
51. Robinson K, Gupta A, Dennis VW y cols. Hyperhomocisteinemia confers an independent increased risk of atherosclerosis in ende-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94:2743-2748.
52. Eikelboom JW, Lonn E, Genest J, Jr., Hankey G, Yusuf S: Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-375.
53. Hankey GJ, Eikelboom JW: Homocysteine and vascular disease. Lancet 1999; 354: 407-413.
54. Christen WG, Ajani UA, Glynn RJ, Hennekens CH: Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000; 160: 422-434.
55. 12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid. Am J Nephrol. 1998; 18:367-372.
56. Van Guldener C, Stam F, Stehouwer CDA: Homocysteine metabolism in renal failure. Kidney Int 2001; 59:234-237.
57. Ross EA, Koo LC, Moberly JB. Low whole blood and erythrocyte levels of glutathione in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1997; 30(4):489-494.
58. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 2001; 60(3):1106-1113.
59. McGregor DO, Dellow WJ, Lever M, George PM, Robson RA, Chambers ST. Dimethylglicine accumulates in uremia and predicts elevated plasma homocyseine concentrations. Kidney Int 2001; 59(6):2267-2272.
60. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114(5):473-501.
61. Suliman ME, Lindholm B, Barany P y cols. Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease. Clin Chem Lab Med 2001; 39(8): 734-738.
62. Mujumdar VS, Aru GM, Tyagi SC. Induction of oxidative stress by homocysteine impairs endothelial function. J Cell Biochem 2001; 82:491-500.
63. Fuchs D, Jaeger M, Widner B, Wirleitner B, Artner-Dworzak E, Leblhuber F. Is hyperhomocysteinemia due to the oxidative depletion of folate rather than to insufficient dietary intake? Clin Chem Lab Med 2001; 39:691-694.
64. Lindholm B, Heimbürger O, Stenvinkel P, Bergström J. Uremic toxicity En: Kopple JD, Massry SG, eds. Nutritional Management of Renal Disease. Philadelphia. Lippincott Williams and Wilkins. 2004: 63-98.
65. McGrecor DO, Dellow WJ, Robson RA, Lever M, George PM, Chambers ST. Betaine supplementation decreases postmethionine hyperhomocysteinemia in chronic renal failure. Kidney Int 2002; 61(6):1041-6.
66. De Gómez NT, Giammona AM, Touceda LA. Variations in the profile of patients with chronic renal failure treated with pyridoxine. Lipids in Health and Disease 2003; 2:7.
67. Jungers P, Joly D, Massy Z, Chauveau P, Nguyen A, Aupetit J, Chadefaux B. Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant 1999; 14:2903-2906.
68. Sunder-Plasssmann G, Fodinger M, Buchmayer H y cols. Effect of High dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000; 11:1109-1116.
69. Poge U, Look M, Gerhardt T, Klehr Hu, Sauerbruch T, Woitas RP. Intravenous treatment of hiperhomocisteinemia in patients on chronic hemodialisis. A pilot study. Ren Fail 2004; 26(6): 703-8.
70. Hunter R, Barnes J, Oakeley HF, Matthews DM. Toxicity of folic acid given in pharmacological doses to health volunteers. Lancet 1970; i:60-63.
71. 12 to any folate fortification or supplement. Am J Clin Nutr 1997; 65:572-573.
72. 12 in patients with chronic renal failure. Nephron Clin Pract 2005; 99:42-48.
73. th ed., edited by Scriver CR, Beaudet AL, Sly WS, Valle D, New York, McGraw-Hill, Inc., 1995: 1283-1284.
74. 1) supplementation does not reduce fasting blood homocysteine concentration in most homozygotes for homocystinuria. Biochim Biophys Acta 1996; 1317:101-104.
75. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-881.
76. Shimakawa T, Nieto FJ, Malinow MR, Chambless LE, Schreiner PJ, Szklo M: Vitamin intake: a possible determinant of plasma homocyst(e)ine among middle-aged adults. Ann Epidemiol 1997; 7: 285-293.
77. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J: Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001; 73: 613-621.
78. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen AL, Schneede J: Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 2000; 46: 1065-1071.
79. Verhoef P, Rimm EB, Hunter DJ, Chen J, Willett WC, Kelsey K, Stampfer MJ: A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: Results among US men. J Am Coll Cardiol 1998; 32: 353-359.
80. Ramírez G, Chen M, Boyce HW, Fuller SM, Ganguly R, Brueggemeyer CD, Butcher DE: Longitudinal follow-up of chronic hemodialysis patients without vitamin supplementation. Kidney Int 1986; 30: 99-106.
81. Niwa T, Ito T, Matsui E: Plasma thiamine levels with hemodialysis. JAMA 1971; 218:885-886.
82. DeBari VA, Frank O, Baker H, Needle MA: Water soluble vitamins in granulocytes, erythrocytes, and plasma obtained from chronic hemodialysis patients. Am J Clin Nutr 1984; 39:410-415.
83. Mydlik M, Derzsiova K, Valek A, Szabo T, Dandar V, Takac M: Vitamins and continuous ambulatory peritoneal dialysis (CAPD). Int Urol Nephrol 1985; 17:281-286.
84. Descombes E, Hanck AB, Fellay G: Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int 1993; 43:1319-1328.
85. 2 and vitamin E in long-term hemodialysis. JAMA 1971; 217:699.
86. Blumberg A, Hanck A, Sander G: Vitamin nutrition in patients on continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1983; 20:244-250.
87. Boeschoten EW, Schrijver J, Krediet RT, Schreurs WH, Arisz L: Deficiencies of vitamins in CAPD patients: the effect of supplementation. Nephrol Dial Transplant 1988; 2:187-193.
88. Sterzel RB, Semar M, Lonergan ET, Treser G, Lange K: Relationship of nervous tissue transketolase to the neuropathy in chronic uremia. J Clin Invest 1971; 50:2295-2304.
89. Kuriyama M, Mizuma A, Yokomine R, Igata A, Otuji Y: Erythrocyte transketolase activity in uremia. Clin Chim Acta 1980; 108:169-177.
90. 6 in patients with chronic renal failure on regular haemodialysis. Eur J Clin Nutr 1992; 46:679-683.